Key Takeaways
- Vir Biotechnology’s stock options are under a lock-up agreement until April 27, 2026.
- The lock-up period begins on February 25, 2026, lasting for 61 days.
- Company executives cannot sell or hedge their shares without consent from Goldman Sachs and Leerink Partners.
Lock-Up Agreement Overview
Vir Biotechnology, Inc. is implementing a lock-up agreement on certain stock options that will last until April 27, 2026. The agreement stipulates that from February 25, 2026, to April 27, 2026, there will be a 61-day lock-up period during which specific parties cannot sell or hedge their shares.
The company, along with its directors and executive officers, has made arrangements with underwriters which prevent them from disposing of any common stock or securities convertible into common stock. This restriction remains in effect from the date of the prospectus supplement for 60 days, unless they receive prior written consent from Goldman Sachs & Co. LLC and Leerink Partners LLC.
This lock-up agreement is a common practice in the financial markets, typically implemented to stabilize stock prices immediately following an IPO or significant equity event. By restricting the sale of shares, it aims to prevent a sudden influx of stock onto the market, which could drive prices down.
Such agreements reflect the company’s confidence in its long-term vision, showing commitment from its leadership team and investors alike. By adhering to these terms, Vir Biotechnology seeks to maintain investor trust and promote market stability as it continues to navigate the complex landscape of biotechnology and pharmaceuticals.
The content above is a summary. For more details, see the source article.